Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

EXTON, Pa., May 1, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced financial results for the first quarter of 2013. Net sales were $107 million for the first quarter ended March 31, 2013 as compared to $136 million in the comparative period of 2012.  The decline in net sales quarter over quarter was driven by the decrease in Vancocin revenues partially offset by commercial product growth for Cinryze. The first quarter 2013 U.S. Cinryze net sales which grew by 44 percent over the first quarter of 2012 to $97 million, including approximately $91 million of patient demand.  The balance represented additional inventory in the channel. 

"The early part of 2013 has seen great progress both in our commercial business as well as our development pipeline," stated Vincent Milano, ViroPharma's chief executive officer. "In addition to the virologic response data we will share during our conference call today from subjects enrolled into our two maribavir studies, we also expect results from several key programs for Cinryze in the coming quarters such as subcutaneous Cinryze administration, antibody-mediated rejection (AMR) in kidney transplant, new uses for C1 INH, as well as additional progress updates with maribavir."

Our GAAP net loss was $64 million in the first quarter of 2013 compared to net income of $20 million in the first quarter of 2012.  GAAP diluted net loss per share was $(0.98) for the first quarter of 2013 compared to GAAP diluted earnings per share of $0.26 for the same period in 2012. The loss for the quarter was driven by a $104 million non-cash impairment charge related to the Vancocin intangible asset due to rapid decline in market price of generic vancomycin. Also driving the quarter over quarter decrease was the loss of Vancocin revenues partially offset by the continued growth of Cinryze.

Non
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Participate in Two December Healthcare Investor Conferences
2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PROVIDENCE, N.J. , Sept. 2, 2014   ... for MassBio,s 20th Annual Golf Classic, a major fundraiser ... event will be held on September 5 at the ... . The MassBioEd Foundation supports ... through educational programs, workforce development, and lifelong learning. ...
(Date:9/2/2014)... nanowires could be used for detailed studies of what ... important for pharmaceuticals research, among other applications. A group ... to make artificial cell membranes form across a large ... All communication between the interior of a cell and ... membrane is a surface layer that holds the cell ...
(Date:9/2/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... and Life Sciences: North America ... market for pharmaceutical, biopharma and life sciences is estimated at ... grow at a CAGR of 9.1% from 2014 to ... million in 2019. Browse the full Global ...
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2
... N.J., June 12 BioNeutral announced today the,results ... anthrax,spores on contact. This chemical technology is designed ... in conjunction with any suspected anthrax,exposure. "The Ygiene(TM) ... in as little as 15 seconds," said Dr. ...
... June 12 GenVault Corporation today,announces Paul J. ... Inc.,has joined its Board of Directors. Mr. Mirabella ... imaging with GE Healthcare where he held,leadership roles ... this substantial background in diagnostics and the healthcare,market, ...
... BRUNSWICK, N.J., June 12 Senesco,Technologies, Inc. ("Senesco" ... announced,that the Company will be presenting at the ... Annual International Convention,which is being held at the ... Galton, Chief Executive Officer of Senesco, will deliver ...
Cached Biology Technology:BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism 2Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVault's Board of Directors 2Senesco Technologies to Present at BIO 2008 Business Forum 2
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... A new study published in the September issue ... , identifies a novel strategy to diagnose the ... before irreversible structural damage has occurred. This advance ... diabetes on the endothelium of retinal vessels. Using ... to distinguish the early molecular development of diabetic ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... presents research on the genetic make-up and biology of ... better diagnosis and treatment of the diarrhea disease giardiasis, ... may also bring an understanding of several vital biological ... parasite that exists all over the world and causes ...
... GMES Programme approved the transition to Phase-2 of Segment ... of the programme by the ESA Council at ministerial ... 2 of 116%, giving a total amount of 500 ... ESA to confirm the development of the first three ...
... Now Fully Supports M2SYS Fingerprint Technology to ... Accurately Verify Check Casher Identity, ... biometric,technology research and development firm, announced today its partnership,with ... solutions, to integrate the M2SYS Bio-Plugin(TM) fingerprint,solution into TeraCash, ...
Cached Biology News:New Swedish research hope for millions of sufferers 2M2SYS Technology Partners with TeraCorp Enterprises to Provide Added Security Within Check Cashing Solution 2
... a chemiluminescent signal enhancing reagent that ... the signal obtained with all ECL ... Plus is derived from a powerful, ... or chemiluminescent substrate enhancers, ChemiLucent™ Plus ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences ... peptide is (amino to carboxy terminus): S(21) - S - M ... D - E - A - I - D - K ... C(39). This peptide may be used for neutralization and ...
... for quantitative assays using recombinant proteins/antibodies ... the flexible and powerful Paraflo microfluidic ... sequences can be synthesized on-chip and ... custom sequence design. These microarrays are ...
Biology Products: